FGL is a synthetic peptide copied from a small part of NCAM, the neural cell adhesion molecule. The name comes from the structure it imitates: the FG loop of the second fibronectin type III module of NCAM. It is 15 amino acids long, and its designed job is to bind and activate fibroblast growth factor receptor 1 (FGFR1), the same receptor NCAM engages on nerve cells (Neeves et al., *Neuroscience*, 2006, PubMed 16784819).
You will also see it written as FGLL (FG loop-loop), the dimeric form used in pharmaceutical development. The two names refer to closely related versions of the same NCAM-mimetic concept.
What the preclinical research found
Most of what is known about FGL comes from animal and cell studies, and there is a fair amount of it. Across those experiments the peptide has been reported to promote neurite outgrowth, support neuron survival, and act through FGFR1 signaling.
Some specific findings:
- In newborn rats given FGL intranasally, the peptide reached blood and cerebrospinal fluid within minutes and was tied to faster early development of motor coordination. In adult rats, a single subcutaneous dose was linked to longer retention of social memory (Neeves et al., 2006).
- A separate study reported that FGL protected hippocampal neurons from simulated ischemic (stroke-like) injury both in cultured cells and in live animals (Skibo et al., *Eur J Neurosci*, 2005, PubMed 16197499).
- Other groups have described anti-inflammatory effects on glial cells and changes in long-term potentiation, a cellular correlate of learning, in rodent models.
These are real, published, peer-reviewed studies. They are also animal and in-vitro work. None of them establishes a benefit in humans.
The one human trial
FGL did reach people, once, in a documented way. A Phase I study gave single intranasal doses (25, 100 and 200 mg) to 24 healthy adult men in an ascending-dose design. All three doses were reported as well tolerated, with no notable changes in ECG, vital signs, or lab tests. The adverse events were minor: transient nasal burning at the top dose, brief eye watering at the lowest. Blood levels rose with dose but peaked low and cleared within a few hours (Anand et al., *Clin Pharmacokinet*, 2007, PubMed 17375985).
That trial was a safety and pharmacokinetics study, not an efficacy study. It tells you the peptide was tolerated at those doses and got into the bloodstream. It does not tell you it works for anything.
Who made it, and where it went
FGL/FGLL was developed by ENKAM Pharmaceuticals (Copenhagen, Denmark) as a candidate for neurodegenerative conditions such as Alzheimer's disease, with support from the EU's PROMEMORIA research programme (Anand et al., 2007). The compound is also covered by patents describing NCAM-derived peptides (US Patent 8,470,964).
There is no evidence that FGL advanced to a successful efficacy trial, and it is not an approved drug anywhere. It has no FDA, EMA, or other regulatory approval for human use.
What this means for buyers
FGL is sold by some research-chemical vendors. A few points worth keeping straight:
- It is research use only and not approved for human consumption. Nothing here is medical or dosing advice.
- Because there is no pharmaceutical-grade source, you are relying entirely on a vendor's own quality control. A peptide this obscure is exactly the kind where identity and purity vary, and a 15-mer can be mis-synthesized or contaminated without that being obvious.
- If a vendor sells it, ask for a recent third-party certificate of analysis (COA) showing mass-spec identity and HPLC purity for that specific batch. peptideone aggregates independent vendor ratings and testing signals where they exist, but for a compound with this little market presence, hard third-party COA data is often thin or absent.
The honest summary: FGL has a genuine scientific story behind it as an NCAM/FGFR1 mimetic, with a real (if early) human safety study, but its evidence stops well short of demonstrated efficacy, and it remains an unapproved experimental peptide.